# A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Source: https://onco.cc/trials/nct06022861/  
OnCo record `nct06022861` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Cisplatin and Nivolumab in oesophageal cancer, run by Shandong Boan Biotechnology Co., Ltd, now recruiting.

## Summary

A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma is a phase 3 interventional study registered as NCT06022861 by Shandong Boan Biotechnology Co., Ltd, with 510 participants planned, started 2023-10-12 and due to reach its primary completion in 2025-06. Interventions recorded: LY01015, Fluorouracil, Cisplatin and Opdivo®.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06022861
- Phase: 3
- Setting: A Randomized, Double-blind, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of LY01015 and Opdivo®（Nivolumab Injection）Combined Respectively With Fluorouracil Plus Cisplatin in Participants With Advanced or Metastatic Esophageal Squamous Cell Carcinoma.
- Sponsor: Shandong Boan Biotechnology Co., Ltd
- Enrolled: 510

## Sources

- ClinicalTrials.gov NCT06022861: https://clinicaltrials.gov/study/NCT06022861

## Connected records

- cancers: [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- companies: [Luye Pharma Group](https://onco.cc/companies/luye-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct06022861.json